Mereo BioPharma (MREO) Current Assets (2017 - 2026)

Mereo BioPharma (MREO) has reported Current Assets for 10 consecutive years, with $40.0 million the latest figure, recorded in Q1 2026.

• Quarterly Current Assets fell 40.16% year-over-year to $40.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $40.0 million (down 40.16% YoY) and the FY2025 annual result came in at $45.0 million, down 39.78% from the prior year.
• Current Assets eased to $40.0 million in Q1 2026 per MREO's latest filing, from $45.0 million in the prior quarter.
• Over the last five years, Current Assets for MREO reached as high as $103.0 million in Q2 2022 and fell as low as $40.0 million in Q1 2026.
• A 5-year average of $67.9 million and a median of $66.9 million in 2025 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2022 — Current Assets slumped 45.57% — and 2024, when it surged 38.43%.
• Year by year, Current Assets stood at $72.9 million in 2022, then fell by 12.51% to $63.8 million in 2023, then advanced by 17.26% to $74.8 million in 2024, then slumped by 39.78% to $45.0 million in 2025, then slipped by 11.08% to $40.0 million in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $40.0 million, $45.0 million, and $52.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.